e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Asthma: clinical aspects and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
D. Romero, J. I. Larco, I. Bobolea, C. Villasante, P. Barranco, S. Quirce, R. Alvarez-Sala (Madrid, Spain)
Source:
Annual Congress 2010 - Asthma: clinical aspects and treatment
Session:
Asthma: clinical aspects and treatment
Session type:
E-Communication Session
Number:
3961
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Romero, J. I. Larco, I. Bobolea, C. Villasante, P. Barranco, S. Quirce, R. Alvarez-Sala (Madrid, Spain). Follow-up of patients with moderate-severe allergic asthma treated with omalizumab. Eur Respir J 2010; 36: Suppl. 54, 3961
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Allergic rhinitis neither routinely diagnosed nor treated in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 249s
Year: 2005
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab
Source: Annual Congress 2012 - Asthma: assessment and treatment
Year: 2012
The effectiveness of omalizumab in steroid-dependent asthma patients
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept